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Recycling old drugs, rescuing shelved drugs and extending patents’ lives make drug repositioning an
attractive form of drug discovery. Drug repositioning accounts for approximately 30% of the newly US
Food and Drug Administration (FDA)-approved drugs and vaccines in recent years. The prevalence of
drug-repositioning studies has resulted in a variety of innovative computational methods for the
identification of new opportunities for the use of old drugs. Questions often arise from customizing or
optimizing these methods into efficient drug-repositioning pipelines for alternative applications. It
requires a comprehensive understanding of the available methods gained by evaluating both biological
and pharmaceutical knowledge and the elucidated mechanism-of-action of drugs. Here, we provide
guidance for prioritizing and integrating drug-repositioning methods for specific drug-repositioning
pipelines.A repositioned drug does not need the initial six to nine years
typically required for the development of new drugs, but instead
goes directly to preclinical testing and clinical trials, thus reducing
risk and costs [1]. Repositioning or repurposing drugs has been
implemented in several ways. One of the well-known examples is
sildenafil citrate (brand name: Viagra), which was repositioned
from a common hypertension drug to a therapy for erectile
dysfunction [2]. Similarly, off-label use of Food and Drug Admin-
istration (FDA)-approved drugs for cancer medical practice is also
popular. The National Comprehensive Cancer Network (NCCN)
estimates off-label use accounts for 50–75% of drugs or biologic
therapies for cancer in the USA [3]. It has been reported that 78%
and 75% of patients with breast or lung cancer, respectively
received FDA-approved drugs, although 68% and 95% of these
drugs, respectively, were used for off-label indications not
approved by the FDA [4]. Obviously, these examples were seren-
dipitously identified and these repositioning strategies lack gui-
dance and information to support clinical decision.
Pharmaceutical companies rely on traditional drug discovery
methods to seek repositioning opportunities. Among the 75 agents
(50 small molecules and 25 biologics) approved between 1999 andCorresponding author:. Wong, Stephen T.C. (stwong@tmhs.org), (EWenzel@tmhs.org)
1359-6446/06/$ - see front matter  2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2008, 28 first-in-class small molecules were discovered by pheno-
typic drug screening and 17 were identified by target-based meth-
ods [5,6], accounting for more than 50% of the FDA-approved
small molecules and biologics. Phenotypic drug-screening
approaches discover drug candidates from libraries serendipi-
tously. Alternatively, target-based methods improve the reposi-
tioning process by including known target information into drug-
repositioning studies.
Nevertheless, the low knowledge content of elucidated mechan-
isms for traditional drug-repositioning methods makes it hard to
satisfy unmet medical needs by successfully repositioning a large
number of existing or shelved drugs. Computational methods are
able to alleviate this problem by high-level integration of available
knowledge and elucidation of unknown mechanisms. These com-
putational methods significantly improve the discovery process in
which new indications for a drug or new drugs for a disease can be
identified. They take advantage of the methods and tools available
in chemoinformatics [7–9], bioinformatics [10–14], network biol-
ogy [15–17] and systems biology [18–20] to make full use of known
targets, drugs, and disease biomarkers or pathways, thus leading
to the development of proof-of-concept methods and the design
of clinical studies with accelerated timelines. Accordingly, com-
putational drug-repositioning methods can be classified into2013.11.005 www.drugdiscoverytoday.com 637
REVIEWS Drug Discovery Today  Volume 19, Number 5 May 2014
Serendipitously
tested and screened
Target
Drug oriented Disease oriented
Drug repositioning
Treatment oriented
Chemical
information
Phenotypic
screening
Clinical adverse
 effects
FDA off-label
use
Pathway
Genetics
Genomics
Genetics
Genomics
Disease omics
data
Proteomics
Metabolics
Proteomics
Metabolics
DNA RNA
protein Targeted
pathway
Drug omics
data
DNA RNA
Protein
Cheminformatics and bioinformatics Network biology and systems biology
Mechanism or knowledge
Blinded
Target
based
Knowledge
based
Signature
based
Pathway or
network based
Targeted mechanism
based
Drug Discovery Today 
FIGURE 1
Lotus leaves flowchart (LLF) for categorization of existing drug-repositioning methods. Drug repositioning takes advantage of different potential avenues to
repurpose drugs for new indications, including drug, disease and treatment oriented. These avenues were developed according to the availability of biological and
pharmaceutical knowledge and requirement of understanding the mechanisms of action of drugs. Traditional phenotype-based screening methods do not need
prior knowledge, and the repositioned drugs are just serendipitously tested. Targeted-based methods need specific knowledge about the targets, such as 3D
protein structures, whereas knowledge-based methods require the knowledge about the drugs or diseases, such as adverse effects, FDA approval labels, records
of clinical trials and published disease biomarkers (potential targets) or disease pathways. Signature-based methods mainly make use of gene signatures defined
by ‘-omics’ data (for diseases, drug treatments, or both). Pathway- or network-based methods generally use pathway analysis or network biology methods to
discover essential pathways from genetic, genomic, proteomic and metabolic data of diseases to find new targets for repositioned drugs. More advanced drug-
repositioning methods, such as targeted mechanism-based methods, aim to discover mechanisms of action of drugs by identification of off-targets or targeted
pathways of treated drugs using drug omics data (before and after drug treatments). Details of these methods are in Table 1 (main text). Integrated knowledge
and elucidated mechanisms of drug actions increases with the complexity of modeling methods.
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work-based, and targeted-mechanism-based methods, as shown in
Fig. 1. These methods focus on different orientations defined by
available information and elucidated mechanisms, such as drug
oriented, disease oriented and treatment oriented. These compu-
tational drug-repositioning methods enable researchers to exam-
ine nearly all drug candidates and test on a relatively large number
of diseases within significantly shortened time lines.
In recent years, the number of drug-repositioning methods has
dramatically increased. It is essential to better understand these
existing methods and prioritize them based on specific studies.
Application of an efficient drug-repositioning pipeline to a specific
study needs identification of feasible methods based on available
information of the drugs or diseases of interest. In this review, we
link existing drug-repositioning methods with their integrated
biological and pharmaceutical knowledge and discuss how to
customize a new drug-repositioning pipeline for specific studies.
Prioritize available drug-repositioning methods
Figure 1 is a top-down flowchart that we developed to better
understand orientations, integrated information types, categories
and complexities of existing drug-repositioning methods. We call
this flowchart a lotus leaves flowchart (LLF). It enables better
understanding of repositioning methods from the top down while638 www.drugdiscoverytoday.comcustomizing new repositioning pipelines from the bottom up. As
an example, if one wants to reposition drugs for an orphan disease,
one needs to identify how much pharmaceutical or biological
knowledge is available for this disease and whether understanding
the mechanisms of action of repositioned drugs is necessary. There
are several options to do such drug repositioning. Option 1: when
little information is available for the disease, phenotypic screening
or FDA off-label use would be the best option. Option 2: if there
exists one protein biomarker for the disease, target-based or knowl-
edge-based methods should be prioritized for the study. Option 3:
if there is more disease information available, either knowledge-
based or signature-based methods can be deployed to integrate
available disease pathways or disease omics data (i.e. omics data
generated from diseases) into the drug-repositioning process.
Lastly, option 4: if treatment omics data (i.e. omics data generated
from drug treatment) are available, it is possible to use signature-
based or targeted-mechanism-based methods to elucidate
unknown targeted mechanisms, such as off-targets and targeted
signaling pathways.
It is easy to see that the development of an efficient drug-
repositioning pipeline is a process of tradeoff among purposes,
methods and available information. Here, we introduce the repo-
sitioning methods shown in the LLF to facilitate understanding
the purpose, the integrated information and the complexities of
Drug Discovery Today  Volume 19, Number 5 May 2014 REVIEWS
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researchers to better understand existing computational methods
and customize these methods into their own pipelines for drug-
repositioning studies.
Blinded search or screening methods
Blinded drug-repositioning methods do not include pharmaceu-
tical or biological information and are less likely to help elucidate
any mechanisms of action of drugs. Most of them depend on
serendipitous identification from tests aimed at specific diseases
and drugs [3,4,21]. The advantage of these methods, which
include FDA off-label use and phenotypic screening, is that they
have high flexibility for application to a large number of drugs or
diseases. This explains why the phenotypic screening method was
used in the discovery of 28 of 75 small molecules and biologics
approved by the FDA between 1999 and 2008.
Target-based methods
Target-based drug-repositioning methods comprise in vitro and in
vivo high-throughput and/or high-content screening (HTS/HCS) of
drugs for a protein or a biomarker of interest [7–9] and in silico
screening of drugs or compounds from drug libraries [7,22], such as
ligand-based screening or docking [23,24]. Compared with blinded
methods, targeted-based methods significantly improve the like-
lihood of drug discovery because most targets link directly with the
disease mechanisms. Integration of target information into the drug
repositioning process ensures a higher possibility of finding useful
drugs compared with traditional blinded methods. The advantage
of targeted-based methods, such as docking, is that these methods
enable researchers to screen nearly all drugs or compounds with
known chemical structure information (e.g. Simplified Molecular-
Input Line-Entry System SMILES) within a few days. This is why so
many pharmaceutical companies, including Genentech and Melior,
have been using these methods to find new indications.
Knowledge-based methods
Knowledge-based drug-repositioning methods are those applying
bioinformatics or cheminformatics approaches to include the
available information of drugs, drug–target networks [10–14],
chemical structures of targets and drugs [14], clinical trial infor-
mation (adverse effects) [25,26], FDA approval labels [27], signal-
ing or metabolic pathways [28], and so on, into drug-repositioning
studies. The information content of blinded and target-based
methods are poor and they cannot be used to identify new
mechanisms beyond the known targets. By contrast, knowl-
edge-based methods incorporate known information into predict-
ing unknown mechanisms, such as unknown targets for drugs,
unknown drug–drug similarities, and new biomarkers for diseases.
The advantage of knowledge-based methods is that they include a
large amount of known information into the drug-repositioning
process to improve its prediction accuracy. For example, THOM-
SON REUTERSTM has used this strategy to do drug repositioning
based on its rich volumes of accumulated prior knowledge. More-
over, these methods have been applied to repurpose known drugs
to pediatric hematology oncology. Blatt and Corey describe how
the knowledge in the Harriet Lane Handbook (HLH) of the Johns
Hopkins School of Medicine (compiled based on perceived interest
to the general pediatric practitioners) and information acquired bysearching PubMed and Google.com might also be helpful to
repurpose drugs for children [29].
Signature-based methods
Signature-based drug-repositioning methods make use of gene sig-
natures derived from disease omics data with or without treatments
[30–37] to discover unknown off-targets or unknown disease
mechanisms. As the advancement of microarray and next genera-
tion sequencing techniques speed up the generation of vast volumes
of genomics data pertinent for drug-repositioning studies, gene
signatures can be used to discover unknown mechanisms.
One can easily access such genomics data in publicly available
databases, such as NCBI-GEO (http://www.ncbi.nlm.nih.gov/
geo/), SRA Sequence Read Archive (http://www.ncbi.nlm.nih.gov/
Traces/sra/), CMAP Connectivity Map [32] and CCLE Cancer Cell
Line Encyclopedia [38]. More details on these databases are shown
in Table 2. The advantage of signature-based methods is that they
are useful to uncover unknown mechanisms of action of molecules
and drugs. Compared with knowledge-based methods, signature-
based methods involve more molecular-level mechanisms, such as
the significantly changed genes, by using computational
approaches.
Pathway- or network-based methods
Pathway- or network-based drug-repositioning methods utilize dis-
ease omics data, available signaling or metabolic pathways, and
protein interaction networks to reconstruct disease-specific path-
ways that provide the key targets for repositioned drugs [15–17]. The
advantage of these methods is that they are helpful in narrowing
general signaling networks from a large number of proteins down to
a specific network with a few proteins (or targets). A recent study of
drug repositioning addressed distinct signaling mechanisms of
metastatic subtypes of breast cancer [17]. Neither knowledge-based
nor signature-based methods can address these repositioning results
because the subtype signaling mechanisms are hard to elucidate
from existing breast cancer pathways or the gene signatures.
Targeted mechanism-based methods
Targeted mechanism-based drug-repositioning methods integrate
treatment omics data, available signaling pathway information
and protein interaction networks to delineate the unknown
mechanisms of action of drugs [18–20]. The era of precision
medicine motivates such drug-repositioning studies. For instance,
drug resistance remains an unresolved issue in cancer therapy.
Although patients respond well to a drug initially, they often
acquire resistance to that drug after a few months of treatment.
This indicates that deriving a successful drug treatment needs
additional information about the mechanisms of action of drugs
to find better drug targets. Systems biology approaches are promis-
ing in addressing this challenge. The advantage of these methods
is that their goals are not only to discover the mechanisms related
to diseases or drugs, but also to identify those directly related to
treatments of drugs to specific diseases. Owing to the difficulties in
deriving effective computational models, there are only a few
studies on these targeted mechanism-based methods [18–20] that
developed elegant computational models to predict the drug
effects and related targeted pathways. Comprehensive overviews
of these drug-repositioning methods are given in Tables 1 and 2.www.drugdiscoverytoday.com 639
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TABLE 1
Details of available drug-repositioning methods
Fields Methods Categories Mechanism or
knowledge
complexity
Approach summaries with
references
Examples
Drug-oriented
FDA off-label use Blinded Serendipitously
tested
Extremely low Clinical decisions [3,4,21] Sildenafil citrate (erectile
dysfunction); rituximab (breast
cancer); fluorouracil (lung cancer)
and etoposide (bladder cancer)
Phenotypic screening Blinded Screening Extremely low In vivo and in vitro HTS/HCS
screening [44–47]
HDECC inhibitors for stem-like lung
cancer cells; widely used in GSK and
Novartis
Phenotypic screening Target based Screening Low In vivo and in vitro HTS/HCS
screening [7–9]
Widely used in Genentech
Target 3D structure,
chemical structure
information of drugs
and ligands
Target based Cheminformatics Low In silico screening [7,22], ligand
based and docking [23,24]
MLR-1023 for diabetes (Melior)
Drug–target information,
chemical structure
information of targets
and drugs
Knowledge
based
Bioinformatics,
Cheminformatics
Moderate Drug–target prediction [10–14] Simvastatin and Ketoconazole
(breast cancer)
Adverse effects (clinical
trial information)
Knowledge
based
Bioinformatics Moderate Using correlation to define disease
adverse effect associations [25], and
adverse effects to define drug
similarity [26]
FDA approval labels
and adverse effects
Knowledge
based
Bioinformatics Moderate Using principal component analysis
to define drug similarity
measurement [27]
Disease-oriented
Available Pathway
information
Knowledge
based
Bioinformatics Moderate Discovery of disease mechanism and
address of key targets [28]
Vismodegib for skin cancer
Disease omics data Signature
based
Bioinformatics Moderate From gene signature (most changed
genes) in disease of interest to
identify key targets [30]
Genetics data Signature
based
Bioinformatics Moderate Genome-wide association study
analysis to identify key targets [31]
Disease omics data,
available pathway
information, and
protein interaction
network
Pathway or
network
based
Network biology High Reconstruction of disease-specific
pathways and networks to identify
key targets [15–17]
Sunitinib and dasatinib for breast
cancer brain metastases
Treatment-oriented
Drug omics data Signature
based
Bioinformatics Moderate Connectivity Map, linking diseases
with treated drugs by using gene
signatures [32–34]
Sirolimus for patients with acute
lymphoblastic leukemia with
dexamethasone resistance
Signature and
network
based
Bioinformatics,
network biology
Moderate Using gene signatures to define the
distances among drugs and then use
community structure to classify drug
[48]
Fasudil (a Rho-kinase inhibitor) for
neurodegenerative disorders
Disease omics and
drug omics data
Signature
based
Bioinformatics High Using both drug and disease gene
signatures to define similarities
between drugs and diseases [35–37]
Cimetidine for lung cancer and
topiramate for Inflammatory bowel
disease
Drug omics data,
disease pathway
and protein
interaction network
Targeted-
mechanism
based
Network biology and
systems biology
Extremely
high
Elucidating targeted pathways for
each treated drugs to define
potential repositioning score [18–20]
Daunorubicin and clomifene for
breast cancer
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pipelines
The low-risk and low-cost drug-repositioning strategies have been
widely used to identify new clinical opportunities for old drugs.
Accordingly, numerous strategies have been developed from drug-
repositioning studies. On the basis of the LLF, we use a fishbone
flowchart to present the existing methods with preclinical and640 www.drugdiscoverytoday.comclinical validations (Fig. 2). The fishbone flowchart helps readers to
understand the existing drug-repositioning pipelines and shows
how to generate new drug-repositioning pipelines.
A general fishbone flowchart of existing methods
The fishbone flowchart includes general methods used for drug-
repositioning studies. Starting with a disease or a drug, one can
Drug Discovery Today  Volume 19, Number 5 May 2014 REVIEWS
TABLE 2
Databases used for drug-repositioning studies
Fields Databases Website Refs
Chemical structure PubChem http://pubchem.ncbi.nlm.nih.gov
Collaborative Drug Discovery Vault https://www.collaborativedrug.com
Drugbank http://www.drugbank.ca/ [49]
Therapeutic Target Database (TTD) http://bidd.nus.edu.sg/group/cjttd/ [50]
Pharmacogenetics Knowledge Base (PharmGKB) http://www.pharmgkb.org/ [51]
DrugMap Central (DMC) http://r2d2drug.org/index.html [42]
ChemSpider http://www.chemspider.com
ChemFrog http://www.chemfrog.com
ChemDB http://www.chemdb.com
iScienceSearch http://cwmglobalsearch.com/gs/Default.aspx
Chemicalize (ChemAxon) http://www.chemicalize.org
DistilBio http://distilbio.com
Target 3D structure RCSB Protein Data Bank (PDB) http://www.rcsb.org
OCA http://oca.weizmann.ac.il/oca-bin/ocamain
OPM (membrane proteins) http://opm.phar.umich.edu
Proteopedia http://proteopedia.org
TOPSAN http://www.topsan.org
Drug–target information Drugbank http://www.drugbank.ca/ [49]
Therapeutic Target Database (TTD) http://bidd.nus.edu.sg/group/cjttd/ [50]
Pharmacogenetics Knowledge Base (PharmGKB) http://www.pharmgkb.org/ [51]
DrugMap Central (DMC) http://r2d2drug.org/index.html [42]
MATADOR (manually annotated) http://matador.embl.de
SuperTarget http://bioinf-apache.charite.de/supertarget_v2/ [52]
STITCH (Chemical-Protein Interactions) http://stitch.embl.de/ [53]
GPCR-Ligand Database (GLIDA) http://pharminfo.pharm.kyoto-u.ac.jp/services/glida/ [54]
Psychoactive Drug Screening Program Ki (PDSP Ki) http://pdsp.med.unc.edu/pdsp.php [55]
BindingDB http://www.bindingdb.org/bind/index.jsp [56]
Adverse effects and clinical trial information SIDER http://sideeffects.embl.de/ [57]
FAERS (US FDA) http://www.fda.gov/Drugs/
Adverse Reaction Database (Canada) http://www.hc-sc.gc.ca
Iowa Drug Information Service (IDIS) http://itsnt14.its.uiowa.edu
Clinicaltrial.gov http://clinicaltrials.gov
DrugMap Central (DMC) http://r2d2drug.org/index.html [42]
FDA label information FDALABEL (US FDA) http://www.fda.gov/ScienceResearch/
BioinformaticsTools/ucm289739.htm
DailyMed (US FDA) http://dailymed.nlm.nih.gov/dailymed/about.cfm
Structured Product Labeling (SPL) http://www.fda.gov/ForIndustry/DataStandards/
StructuredProductLabeling/default.htm
DrugMap Central (DMC) http://r2d2drug.org/index.html [42]
Pathway information NCI Pathway Interaction Database (NCI-PID) http://pid.nci.nih.gov/ [58]
Kyoto Encyclopedia of Genes and Genomes (KEGG) http://www.genome.jp/kegg/ [59]
BioCarta http://www.biocarta.com
Reactome http://www.reactome.org
PathwayCommons http://www.pathwaycommons.org/about/ [60]
DrugMap Central (DMC) http://r2d2drug.org/index.html [42]
Protein interaction information Human Protein Reference Database (HPRD) http://www.hprd.org/ [61]
Biological General Repository for Interaction
Datasets (BioGRID)
http://thebiogrid.org/ [62]
STRING http://string-db.org/ [63]
PathwayCommons http://www.pathwaycommons.org/about/ [60]
MIPS (mammalian protein-protein interaction database) http://mips.helmholtz-muenchen.de/proj/ppi/ [64]
IntAct http://www.ebi.ac.uk/intact/ [65]
Database of Interacting Proteins (DIP) http://dip.doe-mbi.ucla.edu/dip/Main.cgi [66]
Molecular omics data NCBI-GEO http://www.ncbi.nlm.nih.gov/geo/
Sequence Read Archive (SRA) http://www.ncbi.nlm.nih.gov/Traces/sra/
Stanford Microarray Database http://smd.princeton.edu
ArrayExpress http://www.ebi.ac.uk/arrayexpress/
Princeton University MicroArray database (PUMAdb) http://puma.princeton.edu
CellMiner (for NCI-60) http://discover.nci.nih.gov/cellminer/
Oncomine https://www.oncomine.org
Cancer Cell Line Encyclopedia (CCLE) http://www.broadinstitute.org/ccle/home [38]
Genetic data or information dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/
Sequence Read Archive (SRA) http://www.ncbi.nlm.nih.gov/Traces/sra/
Online Mendelian Inheritance in Man (OMIM) http://www.omim.org/ [67]
Drug omics data Connectivity Map (CMAP) http://www.broadinstitute.org/cmap/ [32]
Cancer Cell Line Encyclopedia (CCLE) http://www.broadinstitute.org/ccle/home [38]
NCBI-GEO http://www.ncbi.nlm.nih.gov/geo/
Sequence Read Archive (SRA) http://www.ncbi.nlm.nih.gov/Traces/sra/
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FIGURE 2
Fishbone flowchart of drug-repositioning pipelines. Developed drug-repositioning pipelines comprise at least one of these methods (i.e. blinded, target based,
knowledge based, signature based, pathway or network based, and targeted-mechanism based), preclinical studies (in vitro and/or in vivo validations) and clinical
development (testing the new indications identified from the preclinical development). Development of a new drug-repositioning pipeline for a drug or a disease
of interest should evaluate the priorities of these repositioning methods based on the available information of the drug or the disease. For example, an infectious
disease that only has limited available signaling information related to cell wall and cytoplasmic membrane proteins would lead to high priority of target-based
drug-repositioning studies focusing on these cell wall and cytoplasmic membrane proteins. Many drug-repositioning pipelines can reverse the order of the listed
methods in the fishbone flowchart and make use of them flexibly. As an example, several existing drug-repositioning pipelines first consider pathway- or network-
based drug-repositioning methods to reconstruct disease pathways and then use knowledge-based or targeted-based methods to identify candidate drugs. The
fishbone provides all relevant components of general drug-repositioning pipelines, and one can customize specific drug-repositioning pipelines according to the
available knowledge and information of targeted drugs or diseases. Abbreviations: FDA, Food and Drug Administration; GWAS, genome-wide association study;
HTS/HCS, high-throughput and/or high-content screening; PK/PD, pharmacokinetics/pharmacodynamics.
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tion or prior knowledge about the disease or drug. Then, during
the validation stages, one can decide which in vitro and in vivo
validations are needed for further testing of the newly identified
indication(s). Eventually, the repositioned drugs will enter into
clinical trials to evaluate their efficacy and performance in
patients. Here, we take advantage of already published pipelines
to discuss how to select the best drug-repositioning methods for
specific studies.
Example pipeline 1: neglected tropical diseases (malaria) +
phenotypic screening methods + drug libraries + in vivo
validations ) astemizole
Orphan or rare diseases are those diseases that affect small num-
bers of people compared with the general population (<200,000
patient population per year in the USA) [39,40]. The orphan and/
or rare diseases in developing regions of Africa, Asia and the
Americas are also known as neglected tropical diseases. Most of
these diseases receive less treatment and research funding, which
results in little information about the disease mechanisms.
According to the fishbone flowchart in Fig. 2, the methods invol-
ving little information would be useful to reposition drugs for
these diseases. In one such study using phenotypic screening,
Chong et al. screened 1,937 FDA-approved drugs and 750 drugs642 www.drugdiscoverytoday.comthat were either approved for use abroad or undergoing phase II
clinical trials for inhibition of Plasmodium falciparum growth. They
identified a drug, astemizole, as an antimalarial agent by testing
the drug using two mouse models of malaria [41].
Example pipeline 2: distinct breast cancer metastases +
knowledge-based methods + pathway- or network-based
methods + drug libraries + in vitro and in vivo
validations + clinical trials ) sunitinib for brain metastasis
We remain unclear about the pathways or mechanisms respon-
sible for breast cancer metastasis to brain, bone and lung, leading
to challenges in repositioning drugs for these cancer subtypes.
Knowledge-based methods alone cannot solve this repositioning
issue because these methods provide only general or canonical
breast cancer signaling pathways instead of those specific to
various types of metastasis. In a recent study, knowledge-based
and network-based methods were combined to reconstruct the
signaling networks for these metastatic breast cancer subtypes so
that drug repositioning for each type was feasible to implement
[17]. The knowledge-based method in this study deployed newly
discovered signaling network elements, called cancer signaling
bridges [18], to identify general known signaling information
for breast cancer, whereas the network-based method used a
mathematical model to address the specific signaling networks
Drug Discovery Today  Volume 19, Number 5 May 2014 REVIEWS
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targets in a recently developed drug database, DrugMap Central
[42], 15, nine and two drug candidates were repositioned for brain,
lung and bone metastases, respectively. For breast cancer brain
metastasis, in vitro and in vivo validations were used to test the
efficacies of these 15 drug candidates and two drugs were identified
(sunitinib and dasatinib); the efficacy of sunitinib for breast cancer
brain metastasis is now being tested in a phase II clinical trial
(ClinicalTrials.gov ID: NCT00570908).
Example pipeline 3: treatment omics data (164 drug
compounds) + disease omics data (100 diseases) + signature-
based methods + in vivo validations ) cimetidine for lung
adenocarcinoma
To test a large number of diseases for a specific drug or a large
number of drugs for a specific disease, it is difficult to unify the
needed computational approaches because the available informa-
tion for different diseases or drugs varies. For example, to use
target-based methods to reposition drugs for 100 diseases, one
would have to know the biomarkers or available pathways for each
of these diseases. The knowledge needed for this type of drug
repositioning might be unavailable or difficult to derive from the
literature or available databases. However, one can derive the gene
signatures for these diseases from the publicly available genomics
data. Together with the drug signatures identified from treatment
omics data, Sirota et al. considered signature-based methods to
evaluate the drug–disease scores [37]. On the basis of the drug–
disease score map, they validated cimetidine for lung adenocarci-
noma using tumor xenograft experiments.
Example pipeline 4: treatment omics data (>1000 drug–dose
pairs) + targeted mechanism-based methods + in vitro
validations ) repositioned drugs with targeted mechanisms
In example pipeline 3, there is an issue in the gene signatures for
164 drugs: the treatment gene signatures for the 100 diseases are
only based on treatments on three to five cancer cell lines in the
CMAP database. Thus, when applying these drug gene signatures
to other diseases, it is hard to ensure that the disease–drug scores
are not biased by the limited treatment information. Another
issue encountered with signature-based methods is in evaluating
the accuracy of the large number of predictions on disease–drug
associations. By integrating the targeted mechanisms into the
drug-repositioning process, new computational approaches for
predicting the efficacies of repositioned drugs were tested [18]. It
was confirmed that the analysis could accurately predict clinical
responses to more than 90% of drugs approved by the FDA and
more than 75% of experimental clinical drugs that were tested.
The high accuracy of prediction ensures more favorable reposi-
tioning results for disease–drug associations. To keep the accura-
cies of treatment information, only drugs for three cancer cell
lines were repositioned that were used for treatments in CMAP.
Moreover, the importance of the identified targeted pathways
was addressed by explaining the differences in treatment
responses.
Concluding remarks
Drug-repositioning studies are dependent on the prior knowledge
and available information from specific studies to select anddetermine appropriate repositioning methods. Establishing accu-
rate and efficient drug-repositioning pipelines for specific studies
requires the prioritization of existing computational methods
based on the available knowledge or the development of new
computational methods. In this review, we described the available
drug-repositioning methods according to the categorization of
their integrated knowledge and information. We introduced the
LLF to characterize existing repositioning methods and presented
them in a generalized drug-repositioning pipeline (Fishbone flow-
chart). These flowcharts are powerful tools to understand the
existing drug-repositioning methods and customize them into
new drug-repositioning pipelines for specific studies.
Still, many challenges remain for cost-effective drug-reposi-
tioning studies. Not every existing drug-repositioning study can
be generalized to a new study, especially those including com-
putational methods. One has to evaluate carefully the available
drug-repositioning methods according to the prior knowledge
and available information of the study of interest and determine
which is the best for that study. Another issue for the available
drug-repositioning studies for diseases with low knowledge and
low complexity-of-mechanism is that they have relatively low
success rates. The complexities and richness of information
available to drug-repositioning studies largely determine their
success rates; obviously, knowledge-based and signature-based
methods are more likely to identify more successful repurposed
drugs than are blinded search or screening methods. As an
example, we mentioned drug repositioning for pediatric popu-
lation in the ‘Knowledge-based drug-repositioning methods’
section. The existing studies did not consider the blinded search
or screening methods for drug repositioning for pediatric dis-
eases. Instead, the drug knowledge from HLH, PubMed and
Google, was used in the drug repositioning targeting this special
population [29], because knowledge-based methods consider
the factor of patient variability in the drug-repositioning
process.
In the era of precision medicine, it is important to delineate
disease mechanisms, such as signaling pathways, or treatment
mechanisms, such as off-targets and targeted pathways, to
explain the mechanisms of action of drugs. This also leads to
the application of drug repositioning to new indications for
individual patients. Mechanism-based repositioning approaches
are able to consider fully the heterogeneity and complexity of
patients while reducing the inefficacy and toxicity caused by
patient variability [43]. We would like to emphasize that drug-
repositioning studies have to be solidly grounded on science to be
successful. Toward better drug repositioning, the field needs
better development of more in-depth mechanistic computational
methods or models that can readily be customized into drug-
repositioning pipelines that integrate computational and experi-
mental methods seamlessly to ensure high success rates of reposi-
tioned drugs.
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